Where Multiple Myeloma Fits Into Roundup Litigation
The vast majority of Roundup lawsuits allege that glyphosate, the herbicide active ingredient, caused non-Hodgkin lymphoma, and that is the injury most closely associated with this litigation and the 2015 International Agency for Research on Cancer classification of glyphosate as a probable human carcinogen. A smaller subset of cases specifically allege multiple myeloma, a cancer of plasma cells in the bone marrow, as the resulting injury instead.
The scientific support cited for the multiple myeloma theory includes laboratory research, including a 2019 study in the Journal of Hematology and Oncology, that found glyphosate could activate a biological mechanism linked to genetic mutations associated with both multiple myeloma and non-Hodgkin lymphoma in mice. During ongoing trial testimony, plaintiffs have also presented evidence suggesting a Monsanto-funded researcher may have influenced the international panel review process in a way that excluded multiple myeloma from a key summary document, an allegation Monsanto and Bayer dispute.
The Proposed $7.25 Billion Settlement
In February 2026, Bayer, which acquired Monsanto and inherited the Roundup litigation, announced a proposed 7.25 billion dollar settlement intended to resolve current and future Roundup claims broadly, not limited to any single cancer type. As of this update, the settlement has not received final court approval and faces real pushback, including from law firms questioning whether the compensation structure adequately values claims, since reported figures suggest a wide range from roughly 6,000 dollars up to an average of about 165,000 dollars depending on the claim.
The proposal has also been the subject of a jurisdictional dispute over whether it should be transferred into the existing federal multidistrict litigation, a move the judge overseeing that MDL has reportedly been skeptical of and which Bayer may contest. Until final court approval is granted, existing individual lawsuits, including multiple myeloma claims, generally continue to proceed on their own separate tracks.
A Major June 2026 Supreme Court Ruling
A separate, highly significant legal development occurred in June 2026, when the Supreme Court ruled in favor of Monsanto on a preemption question, holding that a specific failure-to-warn claim brought in Missouri state court was preempted by federal law, meaning federal pesticide regulation can, in certain circumstances, block a state law claim that a company should have added a stronger cancer warning to its label.
This ruling could have significant implications for pending and future Roundup cases, including multiple myeloma claims, depending on how broadly lower courts apply it to failure-to-warn theories generally. Because this is a genuinely fast-moving and legally significant moment, with a huge proposed settlement, an unresolved MDL transfer question, and a major Supreme Court ruling all unfolding close together, anyone with a pending or potential claim should get current, individualized legal advice rather than relying on general information about where things stood even a few months earlier.
How to Get Legal Help
If you developed multiple myeloma or another blood cancer after regular, long-term exposure to Roundup or another glyphosate-based herbicide, gather documentation of your exposure, including how long and how often you used the product and whether you used protective equipment, along with your diagnosis records. Because a large proposed settlement and a major Supreme Court ruling are both unfolding, an attorney experienced in this litigation can explain how these developments might affect your specific situation.
To follow any further developments, bookmark this page and subscribe to LawsuitWatch alerts.
Free Legal Evaluation
Do You Qualify to File a Claim?
Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.
Roundup Multiple Myeloma Lawsuit: The Science, and a Proposed $7.25 Billion Deal: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
Does the Roundup lawsuit cover multiple myeloma?
A smaller subset of Roundup cases specifically allege multiple myeloma, distinct from the more common non-Hodgkin lymphoma claims that make up most of the litigation. Some laboratory research has linked glyphosate exposure to a mechanism associated with both cancers.
What is the $7.25 billion settlement?
A proposed global settlement announced by Bayer in February 2026 intended to resolve current and future Roundup claims broadly. It has not received final court approval and faces pushback over its compensation structure, with reported individual payouts ranging widely.
What did the Supreme Court rule in June 2026?
That a specific Missouri state-court failure-to-warn claim against Monsanto was preempted by federal law, meaning federal pesticide regulation can, in some circumstances, block certain state-law labeling claims. This could affect other pending Roundup cases.
Is the litigation over now?
No. As of this update, the proposed settlement is unresolved, a jurisdictional dispute over an MDL transfer is ongoing, and the effect of the Supreme Court preemption ruling on other cases remains to be seen. Individual cases continue separately in the meantime.
What should I do if I have multiple myeloma and used Roundup?
Document your exposure history, including duration, frequency, and protective equipment used, along with your diagnosis, and consult an attorney experienced in this litigation, since several major developments are unfolding that could affect your options.